| Literature DB >> 30887397 |
Nadjania Saraiva de Lira Silva1,2, Bruna Cristina Borges2, Aline Alves da Silva2, Patrícia de Castilhos2, Thaíse Lara Teixeira2, Samuel Cota Teixeira2, Marlus Alves Dos Santos2, João Paulo Silva Servato3, Allisson Benatti Justino4, Douglas Carvalho Caixeta4, Tatiana Carla Tomiosso2, Foued Salmen Espindola4, Claudio Vieira da Silva5.
Abstract
IL-9 is a pleiotropic cytokine, recently recognized as belonging to Th9 cells that are involved in various pathologies. We aimed to evaluate the role of IL-9 in the course of hepatic and renal fibrosis. Female C57BL/6 mice were treated subcutaneously with IL-9 10 ng/mouse and 20 ng/mouse for 40 days, alternating every 5 days each application, the negative control of which was treated with PBS and positive control with CCL4. IL-9 demonstrated fibrogenic activity, leading to increased collagen I and III deposition in both liver and kidney, as well as triggering lobular hepatitis. In addition, IL-9 induced an inflammatory response with recruitment of lymphocytes, neutrophils, and macrophages to both organs. The inflammation was present in the region of the portal and parenchymal zone in the liver and in the cortical and medullary zone in the kidney. IL-9 deregulated liver and kidney antioxidant activities. Our results showed that IL-9 was able to promote hepatorenal dysfunction. Moreover, IL-9 poses as a promising target for therapeutic interventions.Entities:
Keywords: fibrosis; inflammation; interleukin 9; kidney; liver; oxidative stress
Mesh：
Substances：
Year: 2019 PMID： 30887397 DOI： 10.1007/s10753-019-00997-0
Source DB: PubMed Journal: Inflammation ISSN： 0360-3997 Impact factor: 4.092